Davis Polk advised the joint book-running managers for the public offering of common stock by Ardelyx, Inc for gross proceeds of approximately $144 million, including the full exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the Nasdaq Global Market under the symbol “ARDX.”

Based in Fremont, California, Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on enhancing the way patients with cardiorenal and gastrointestinal diseases are treated by using the gut as the gateway to delivering medicines that matter.

The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Donald K. Lang and Sherry Tan. The tax team included partner Rachel D. Kleinberg and associate Adam R. Brownstone. The intellectual property and technology team included partner Frank J. Azzopardi and associate Jennifer Leather. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post